<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224639</url>
  </required_header>
  <id_info>
    <org_study_id>INV-DEN-102</org_study_id>
    <secondary_id>U1111-1181-8290</secondary_id>
    <nct_id>NCT01224639</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever</brief_title>
  <official_title>Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inviragen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine
      Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous
      (SC) or intradermal (ID) injection at two dose levels (low and high). The vaccine will be
      given as two doses 90 days apart. Safety assessments include injection site evaluation and
      adverse events. The immune response generated after vaccination will be assessed up to 9
      months after the first vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, placebo-controlled, randomized study assessing the safety and
      tolerability of two dose levels (low and high) of TDV administered subcutaneously or
      intradermally in two doses separated by an interval of 90 days. Initial dosing of low dose
      cohort will be performed and Day 21 safety assessed prior to administration of second dose to
      low dose cohort on Day 90 and initial dosing of high dose cohort. Day 21 safety for the high
      dose cohort will be assessed prior to administration of second dose for this cohort. Safety
      (local injection site reactions and solicited and unsolicited adverse events) will be
      assessed through Day 120 post-first (1 month after the second dose). Immunogenicity will be
      assessed at specified time points up to Day 120 post-prime (1 month after the second dose)
      and again on Days 180 and 270 (6 and 9 months post-first).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2010</start_date>
  <completion_date type="Actual">November 9, 2011</completion_date>
  <primary_completion_date type="Actual">June 9, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local Injection Site Reaction by Severity</measure>
    <time_frame>Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)</time_frame>
    <description>Solicited local reactions were reported using a participant diary. Pain was categorized as Mild (aware of pain but it does not interfere with daily activity and no pain medication is taken); Moderate (aware of pain; there is interference with daily activity or it requires use of pain medication); Severe (aware of pain and it prevents daily activity), redness was categorized as Mild (greater than [&gt;] 15 millimeter [mm]); Moderate as (15-30 mm); Severe (&gt;30 mm), swelling was categorized as Mild (&lt;15 mm); Moderate (15-30 mm); Severe (&gt;30 mm), and itching was categorized as Mild (slight itching at injection site); Moderate (moderate itching at injection extremity); Severe (itching over entire body).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Systemic Adverse Events (AEs) by Severity</measure>
    <time_frame>Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)</time_frame>
    <description>Solicited systemic AEs were reported using a participant diary. Solicited systemic AEs included fever (&gt;= 37.8Â°C), headache, muscle pain, joint pain, eye pain, photophobia, fatigue, body rash, nausea, vomiting and other (any other symptom not listed in the diary) and were categorized as Mild: transient symptoms, discomfort noticed but easily tolerated, no interference to normal daily activities; Moderate: marked symptoms, moderate interference with daily activities; Severe: considerable interference with daily activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local and Systemic AEs</measure>
    <time_frame>Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Local and Systemic AEs</measure>
    <time_frame>Baseline up to 30 days after second vaccination (Day 120)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes After First Vaccination</measure>
    <time_frame>Days 14, 30, 60 and 90 after first vaccination</time_frame>
    <description>GMT was assessed for the four dengue serotypes: Dengue TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95 percent (%) confidence interval (CIs) were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of All Four Dengue Serotypes After Second Vaccination</measure>
    <time_frame>Days 14 and 30 after second vaccination (Day 104 and 120 respectively)</time_frame>
    <description>GMT was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95% CIs were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Seroconversion to Each of Four Dengue Serotypes After the First Vaccination</measure>
    <time_frame>Days 14, 30, 60 and 90 after first vaccination</time_frame>
    <description>Seroconversion was defined as a Plaque Reduction Neutralization Test (PRNT) titer resulting in 50% reduction in plaques (PRNT[50]) &gt;=10 (if the pre-vaccination PRNT[50] value was &lt;10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was &gt;=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was &gt;=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Seroconversion to Each of Four Dengue Serotypes After the Second Vaccination</measure>
    <time_frame>Days 14 and 30 after second vaccination (Days 104 and 120 respectively)</time_frame>
    <description>Seroconversion was defined as a PRNT titer resulting in 50% reduction in plaques (PRNT[50]) &gt;=10 (if the pre-vaccination PRNT[50] value was &lt;10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was &gt;=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was &gt;=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit (n).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Durability of Immune Response</measure>
    <time_frame>Days 180 and 270</time_frame>
    <description>Immune response was considered durable if the participant had detectable neutralizing antibodies (seroconversion) to all 4 dengue serotypes at 90 and 180 days after the second dose (i.e. Days 180 and 270, respectively). Seroconversion is defined as post-vaccination PRNT(50) titer &gt;=10 where pre-vaccination PRNT 50 titer &lt;10, or post-vaccination PRNT(50) Titer &gt;=4-fold the pre-vaccination PRNT(50) titer value where pre-vaccination PRNT(50) titer &gt;=10. Percentage of participants with seroconversion on Days 180 and 270 are based on the number of participants in the FAS with non-missing MN assay samples at each visit. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strain Serotypes After the First and Second Vaccination</measure>
    <time_frame>Baseline and at multiple time points up to Day 14 after each vaccination</time_frame>
    <description>Serotype-specific vaccine viremia was assessed for the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Only those serotypes and time-points where at least 1 participant had serotype-specific vaccine viremia detection were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Vaccine Viremia</measure>
    <time_frame>14 Days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Vaccine Viremia</measure>
    <time_frame>14 Days after each vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Group 1: Low Dose; SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Low Dose; ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: High Dose; SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: High Dose; ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (SC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (ID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDV - Low Dose</intervention_name>
    <description>TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU</description>
    <arm_group_label>Group 1: Low Dose; SC</arm_group_label>
    <arm_group_label>Group 2: Low Dose; ID</arm_group_label>
    <other_name>Live attenuated tetravalent dengue vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDV - High Dose</intervention_name>
    <description>TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.</description>
    <arm_group_label>Group 3: High Dose; SC</arm_group_label>
    <arm_group_label>Group 4: High Dose; ID</arm_group_label>
    <other_name>Live attenuated tetravalent dengue vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate Buffered Saline (PBS)</description>
    <arm_group_label>Placebo (SC)</arm_group_label>
    <arm_group_label>Placebo (ID)</arm_group_label>
    <other_name>PBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male or female aged 18 to 45 years, inclusive, at time of screening.

          -  Is in good health as determined by medical history, physical examination, and clinical
             safety laboratory examinations.

          -  Has body mass index (BMI) in the range 18-27 kilogram per square meter (kg/m^2).

          -  Has negative serology for Human Immunodeficiency Virus (HIV), Hepatitis C antibody,
             and Hepatitis B surface antigen.

          -  Females of child bearing potential must have a negative urine pregnancy test result
             during screening and a negative urine pregnancy test immediately prior to vaccination
             and be willing to use oral, implantable, transdermal or injectable contraceptives or
             another reliable means of contraception approved by the Investigator (intrauterine
             device, female condom, diaphragm with spermicidal, cervical cap, use of condom by the
             sexual partner or a sterile sexual partner, or abstinence) from screening until after
             the last blood sample (at Day 270).

          -  Is willing and able to give written informed consent to participate.

          -  Is willing and able to communicate with the Investigator and understand the
             requirements of the study.

        Exclusion Criteria:

          -  Has any condition which would limit the participant's ability to complete the study.

          -  Clinically significant hematological, renal, hepatic, pulmonary, central nervous
             system, cardiovascular or gastrointestinal disorders.

          -  Has abnormal electrocardiogram (ECG).

          -  Has febrile illness (temperature greater than or equal to (&gt;=) 38 degree Celsius (Â°C)
             or 100.4 degree Fahrenheit (Â°F) or moderate or severe acute illness or infection
             within three days of vaccination.

          -  Diabetes mellitus.

          -  Has allergy to penicillin, neomycin, streptomycin or gentamicin.

          -  Hypersensitivity to any vaccine.

          -  Seropositivity to any of the four dengue serotypes (TDV-1, TDV-2, TDV-3 or TDV-4),
             yellow fever (YF) virus or West Nile (WN) virus.

          -  Has previous vaccination (in a clinical trial or with an approved product) against
             flaviviruses including dengue, YF or WN.

          -  Has planned vaccination against YF throughout the duration of this study.

          -  Has receipt of any vaccine in the 4 weeks preceding the first trial vaccination.

          -  Planned receipt of any vaccine in the 4 weeks following each of the vaccinations in
             this study.

          -  Travel to dengue-endemic areas in the two months prior to study start or planned
             travel to dengue-endemic areas during the study period, including low altitude regions
             of Colombia where dengue is endemic.

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months
             prior to the first vaccination, or long- term (at least 2 weeks within the previous 3
             months) systemic corticosteroids therapy (at a dose of at least 0.5 milligram per
             kilogram per day [mg/kg/day]) prior to the first vaccination.

          -  Has a history of recurring migraines or on prescription medication for treatment of
             recurring headaches or migraines.

          -  Use of any non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen or
             antihistamines for the 3 days immediately prior to each vaccination.

          -  Use of prescription or over the counter medications 7 days before the first
             vaccination (Day 0), excluding contraceptives and painkillers containing NSAIDs or
             acetaminophen, cold remedies, hormone replacement and antihistamines.

          -  Positive urine screen for cocaine, amphetamines, opiates, or cannabinoids.

          -  Receipt of any other investigational product or participation in any other clinical
             trial in the month before the first vaccination (Day 0) or during the conduct of this
             study.

          -  Receipt of blood products or immunoglobulins 8 weeks before the first vaccination (Day
             0) or planned use during the study period.

          -  Donation of blood 6 weeks before the first vaccination (Day 0) or at any time during
             the study.

          -  Females who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan D Velez, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PECET, Universidad the Antioquia, Medellin, Colombia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Program For The Study and Control of Tropical Diseases</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <results_first_submitted>January 9, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2017</results_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dengue fever</keyword>
  <keyword>live attenuated tetravalent dengue vaccine</keyword>
  <keyword>TDV</keyword>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Colombia from 11 October 2010 to 09 November 2011.</recruitment_details>
      <pre_assignment_details>Healthy male and female participants were enrolled in 1 of the 8 treatment groups: Low Dose Subcutaneous:TDV, Low Dose Subcutaneous: Placebo, Low Dose Intradermal:TDV, Low Dose Intradermal:Placebo, High Dose Subcutaneous:TDV, High Dose Subcutaneous:Placebo, High Dose Intradermal:TDV, High Dose Intradermal:Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Subcutaneous: TDV</title>
          <description>TDV 0.5 milliliter (mL), injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). Takedaâs Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 plaque forming units (PFU), TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Subcutaneous: Placebo</title>
          <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Intradermal: TDV</title>
          <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
        </group>
        <group group_id="P4">
          <title>Low Dose Intradermal: Placebo</title>
          <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="P5">
          <title>High Dose Subcutaneous: TDV</title>
          <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
        </group>
        <group group_id="P6">
          <title>High Dose Subcutaneous: Placebo</title>
          <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="P7">
          <title>High Dose Intradermal: TDV</title>
          <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
        </group>
        <group group_id="P8">
          <title>High Dose Intradermal: Placebo</title>
          <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Subcutaneous: TDV</title>
          <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Subcutaneous: Placebo</title>
          <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Intradermal: TDV</title>
          <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
        </group>
        <group group_id="B4">
          <title>Low Dose Intradermal: Placebo</title>
          <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="B5">
          <title>High Dose Subcutaneous: TDV</title>
          <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
        </group>
        <group group_id="B6">
          <title>High Dose Subcutaneous: Placebo</title>
          <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="B7">
          <title>High Dose Intradermal: TDV</title>
          <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
        </group>
        <group group_id="B8">
          <title>High Dose Intradermal: Placebo</title>
          <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="21"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="18"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to (&gt;=) 18 and &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>The baseline measure category &quot;other&quot; refers to mixed race.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local Injection Site Reaction by Severity</title>
        <description>Solicited local reactions were reported using a participant diary. Pain was categorized as Mild (aware of pain but it does not interfere with daily activity and no pain medication is taken); Moderate (aware of pain; there is interference with daily activity or it requires use of pain medication); Severe (aware of pain and it prevents daily activity), redness was categorized as Mild (greater than [&gt;] 15 millimeter [mm]); Moderate as (15-30 mm); Severe (&gt;30 mm), swelling was categorized as Mild (&lt;15 mm); Moderate (15-30 mm); Severe (&gt;30 mm), and itching was categorized as Mild (slight itching at injection site); Moderate (moderate itching at injection extremity); Severe (itching over entire body).</description>
        <time_frame>Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)</time_frame>
        <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Injection Site Reaction by Severity</title>
          <description>Solicited local reactions were reported using a participant diary. Pain was categorized as Mild (aware of pain but it does not interfere with daily activity and no pain medication is taken); Moderate (aware of pain; there is interference with daily activity or it requires use of pain medication); Severe (aware of pain and it prevents daily activity), redness was categorized as Mild (greater than [&gt;] 15 millimeter [mm]); Moderate as (15-30 mm); Severe (&gt;30 mm), swelling was categorized as Mild (&lt;15 mm); Moderate (15-30 mm); Severe (&gt;30 mm), and itching was categorized as Mild (slight itching at injection site); Moderate (moderate itching at injection extremity); Severe (itching over entire body).</description>
          <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Systemic Adverse Events (AEs) by Severity</title>
        <description>Solicited systemic AEs were reported using a participant diary. Solicited systemic AEs included fever (&gt;= 37.8Â°C), headache, muscle pain, joint pain, eye pain, photophobia, fatigue, body rash, nausea, vomiting and other (any other symptom not listed in the diary) and were categorized as Mild: transient symptoms, discomfort noticed but easily tolerated, no interference to normal daily activities; Moderate: marked symptoms, moderate interference with daily activities; Severe: considerable interference with daily activities.</description>
        <time_frame>Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)</time_frame>
        <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Adverse Events (AEs) by Severity</title>
          <description>Solicited systemic AEs were reported using a participant diary. Solicited systemic AEs included fever (&gt;= 37.8Â°C), headache, muscle pain, joint pain, eye pain, photophobia, fatigue, body rash, nausea, vomiting and other (any other symptom not listed in the diary) and were categorized as Mild: transient symptoms, discomfort noticed but easily tolerated, no interference to normal daily activities; Moderate: marked symptoms, moderate interference with daily activities; Severe: considerable interference with daily activities.</description>
          <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Local and Systemic AEs</title>
        <time_frame>Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)</time_frame>
        <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local and Systemic AEs</title>
          <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Local and Systemic AEs</title>
        <time_frame>Baseline up to 30 days after second vaccination (Day 120)</time_frame>
        <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Local and Systemic AEs</title>
          <population>The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes After First Vaccination</title>
        <description>GMT was assessed for the four dengue serotypes: Dengue TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95 percent (%) confidence interval (CIs) were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.</description>
        <time_frame>Days 14, 30, 60 and 90 after first vaccination</time_frame>
        <population>The full analysis set (FAS) included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received. Here 'n' is number of participants with non-missing microneutralization (MN) Assay samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes After First Vaccination</title>
          <description>GMT was assessed for the four dengue serotypes: Dengue TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95 percent (%) confidence interval (CIs) were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.</description>
          <population>The full analysis set (FAS) included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received. Here 'n' is number of participants with non-missing microneutralization (MN) Assay samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 TDV-1 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.45" lower_limit="8.32" upper_limit="18.61"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="22.08" lower_limit="12.64" upper_limit="38.58"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="111.29" lower_limit="58.46" upper_limit="211.83"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="72.66" lower_limit="27.52" upper_limit="191.86"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-2 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" lower_limit="4.31" upper_limit="11.19"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="7.43" lower_limit="4.89" upper_limit="11.29"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="6.73" lower_limit="4.72" upper_limit="9.59"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="7.64" lower_limit="3.39" upper_limit="17.20"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-3 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.93" lower_limit="8.20" upper_limit="39.17"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="20.00" lower_limit="9.17" upper_limit="43.60"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="26.04" lower_limit="12.30" upper_limit="55.13"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="117.58" lower_limit="41.32" upper_limit="334.54"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-4 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" lower_limit="5.02" upper_limit="11.96"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="11.04" lower_limit="6.26" upper_limit="19.46"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="5.71" lower_limit="4.72" upper_limit="6.90"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="11.22" lower_limit="5.40" upper_limit="23.32"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-1(n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.79" lower_limit="26.00" upper_limit="95.36"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="48.76" lower_limit="27.94" upper_limit="85.09"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="208.37" lower_limit="102.74" upper_limit="422.61"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="153.96" lower_limit="80.16" upper_limit="295.69"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-2 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.60" lower_limit="73.44" upper_limit="1800.07"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="475.52" lower_limit="88.35" upper_limit="2559.42"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="8682.13" lower_limit="5174.46" upper_limit="14567.58"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="2370.24" lower_limit="718.63" upper_limit="7817.74"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-3 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.82" lower_limit="9.77" upper_limit="68.26"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="67.83" lower_limit="25.66" upper_limit="179.29"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="42.03" lower_limit="22.35" upper_limit="79.05"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="307.91" lower_limit="115.76" upper_limit="819.04"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-4 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="14.01" upper_limit="79.31"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="57.51" lower_limit="21.68" upper_limit="152.57"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="9.06" lower_limit="4.89" upper_limit="16.79"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="22.88" lower_limit="10.76" upper_limit="48.69"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-1 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.79" lower_limit="23.98" upper_limit="103.39"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="38.70" lower_limit="19.18" upper_limit="78.08"/>
                    <measurement group_id="O4" value="6.30" lower_limit="2.33" upper_limit="17.02"/>
                    <measurement group_id="O5" value="103.28" lower_limit="50.97" upper_limit="209.26"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="86.40" lower_limit="39.48" upper_limit="189.10"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-2 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.44" lower_limit="66.23" upper_limit="801.82"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="262.51" lower_limit="63.99" upper_limit="1076.87"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="1280.00" lower_limit="768.38" upper_limit="2132.27"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="838.01" lower_limit="375.38" upper_limit="1870.77"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-3 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.57" lower_limit="14.13" upper_limit="84.59"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="50.40" lower_limit="20.72" upper_limit="122.56"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="30.99" lower_limit="18.33" upper_limit="52.37"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="148.14" lower_limit="50.82" upper_limit="431.83"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-4 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.39" lower_limit="7.04" upper_limit="25.46"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="26.48" lower_limit="10.42" upper_limit="67.30"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="5.58" lower_limit="4.43" upper_limit="7.02"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="10.60" lower_limit="5.31" upper_limit="21.13"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-1 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.57" lower_limit="16.17" upper_limit="73.92"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="43.44" lower_limit="18.91" upper_limit="99.80"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="109.09" lower_limit="49.55" upper_limit="240.18"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="80.00" lower_limit="33.72" upper_limit="189.78"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-2 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.80" lower_limit="55.42" upper_limit="596.40"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="309.61" lower_limit="94.50" upper_limit="1014.43"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="1912.01" lower_limit="1254.58" upper_limit="2913.94"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="666.63" lower_limit="305.13" upper_limit="1456.45"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-3 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.99" lower_limit="13.75" upper_limit="69.81"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="60.43" lower_limit="27.22" upper_limit="134.18"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="34.57" lower_limit="20.61" upper_limit="57.99"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="135.92" lower_limit="51.41" upper_limit="359.33"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-4 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.16" lower_limit="6.11" upper_limit="20.38"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="28.29" lower_limit="11.62" upper_limit="68.86"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="6.22" lower_limit="5.12" upper_limit="7.56"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="11.30" lower_limit="5.86" upper_limit="21.81"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs of All Four Dengue Serotypes After Second Vaccination</title>
        <description>GMT was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95% CIs were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.</description>
        <time_frame>Days 14 and 30 after second vaccination (Day 104 and 120 respectively)</time_frame>
        <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received. Here 'n' is number of participants with non-missing MN Assay samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs of All Four Dengue Serotypes After Second Vaccination</title>
          <description>GMT was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95% CIs were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.</description>
          <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received. Here 'n' is number of participants with non-missing MN Assay samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 104 TDV-1 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.09" lower_limit="45.46" upper_limit="271.46"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="137.92" lower_limit="68.77" upper_limit="276.60"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="244.39" lower_limit="133.53" upper_limit="447.30"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="230.93" lower_limit="131.23" upper_limit="406.38"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-2 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.18" lower_limit="76.63" upper_limit="644.18"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="341.84" lower_limit="102.43" upper_limit="1140.85"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="1382.48" lower_limit="935.89" upper_limit="2042.17"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="589.88" lower_limit="277.32" upper_limit="1254.75"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-3 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.03" lower_limit="33.64" upper_limit="158.56"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="144.92" lower_limit="81.49" upper_limit="257.70"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="63.50" lower_limit="45.45" upper_limit="88.71"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="250.56" lower_limit="127.21" upper_limit="493.50"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-4 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.51" lower_limit="11.58" upper_limit="39.95"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="72.46" lower_limit="35.46" upper_limit="148.05"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="10.39" lower_limit="7.09" upper_limit="15.24"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="27.71" lower_limit="14.56" upper_limit="52.77"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-1(n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.55" lower_limit="52.36" upper_limit="315.60"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="92.81" lower_limit="47.92" upper_limit="179.77"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="181.82" lower_limit="101.33" upper_limit="326.24"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="160.00" lower_limit="91.07" upper_limit="281.09"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-2 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.55" lower_limit="64.16" upper_limit="664.90"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="314.76" lower_limit="95.01" upper_limit="1042.74"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="1536.13" lower_limit="972.63" upper_limit="2426.11"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="543.69" lower_limit="248.70" upper_limit="1188.55"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-3 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.14" lower_limit="33.72" upper_limit="141.77"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="88.33" lower_limit="46.17" upper_limit="168.99"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="78.56" lower_limit="49.89" upper_limit="123.70"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="271.84" lower_limit="126.94" upper_limit="582.17"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-4 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.74" lower_limit="10.59" upper_limit="40.64"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="48.76" lower_limit="24.58" upper_limit="96.74"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="9.64" lower_limit="6.41" upper_limit="14.51"/>
                    <measurement group_id="O6" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O7" value="16.99" lower_limit="9.34" upper_limit="30.90"/>
                    <measurement group_id="O8" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Seroconversion to Each of Four Dengue Serotypes After the First Vaccination</title>
        <description>Seroconversion was defined as a Plaque Reduction Neutralization Test (PRNT) titer resulting in 50% reduction in plaques (PRNT[50]) &gt;=10 (if the pre-vaccination PRNT[50] value was &lt;10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was &gt;=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was &gt;=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit.</description>
        <time_frame>Days 14, 30, 60 and 90 after first vaccination</time_frame>
        <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Seroconversion to Each of Four Dengue Serotypes After the First Vaccination</title>
          <description>Seroconversion was defined as a Plaque Reduction Neutralization Test (PRNT) titer resulting in 50% reduction in plaques (PRNT[50]) &gt;=10 (if the pre-vaccination PRNT[50] value was &lt;10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was &gt;=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was &gt;=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit.</description>
          <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 TDV-1 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="90.5" lower_limit="69.8" upper_limit="98.8"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-2 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="1.3" upper_limit="33.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="11.1" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-3 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="28.9" upper_limit="75.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="42.9" lower_limit="21.8" upper_limit="66.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-4 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="6.1" upper_limit="45.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="33.3" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="38.9" lower_limit="17.2" upper_limit="64.3"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-1 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="90.5" lower_limit="69.6" upper_limit="98.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-2 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="88.9" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-3 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.4" lower_limit="72.7" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 TDV-4 (n=19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="23.8" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-1 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O4" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O5" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-2 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="54.4" upper_limit="93.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.4" lower_limit="72.7" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-3 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="88.9" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 TDV-4 (n=19, 5, 21, 3, 19, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="24.4" upper_limit="71.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="42.9" lower_limit="21.8" upper_limit="66.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="33.3" lower_limit="13.3" upper_limit="59.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-1 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-2 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-3 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 TDV-4 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="26.3" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="41.2" lower_limit="18.4" upper_limit="67.1"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Seroconversion to Each of Four Dengue Serotypes After the Second Vaccination</title>
        <description>Seroconversion was defined as a PRNT titer resulting in 50% reduction in plaques (PRNT[50]) &gt;=10 (if the pre-vaccination PRNT[50] value was &lt;10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was &gt;=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was &gt;=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit (n).</description>
        <time_frame>Days 14 and 30 after second vaccination (Days 104 and 120 respectively)</time_frame>
        <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Seroconversion to Each of Four Dengue Serotypes After the Second Vaccination</title>
          <description>Seroconversion was defined as a PRNT titer resulting in 50% reduction in plaques (PRNT[50]) &gt;=10 (if the pre-vaccination PRNT[50] value was &lt;10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was &gt;=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was &gt;=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit (n).</description>
          <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 104 TDV-1 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-2 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-3 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-4 (n=19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="90.5" lower_limit="69.6" upper_limit="98.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="55.6" lower_limit="30.8" upper_limit="78.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-1 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-2 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="54.4" upper_limit="93.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-3 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 TDV-4 (n=19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="47.4" lower_limit="24.4" upper_limit="71.1"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="76.5" lower_limit="50.1" upper_limit="93.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Durability of Immune Response</title>
        <description>Immune response was considered durable if the participant had detectable neutralizing antibodies (seroconversion) to all 4 dengue serotypes at 90 and 180 days after the second dose (i.e. Days 180 and 270, respectively). Seroconversion is defined as post-vaccination PRNT(50) titer &gt;=10 where pre-vaccination PRNT 50 titer &lt;10, or post-vaccination PRNT(50) Titer &gt;=4-fold the pre-vaccination PRNT(50) titer value where pre-vaccination PRNT(50) titer &gt;=10. Percentage of participants with seroconversion on Days 180 and 270 are based on the number of participants in the FAS with non-missing MN assay samples at each visit. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution.</description>
        <time_frame>Days 180 and 270</time_frame>
        <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Durability of Immune Response</title>
          <description>Immune response was considered durable if the participant had detectable neutralizing antibodies (seroconversion) to all 4 dengue serotypes at 90 and 180 days after the second dose (i.e. Days 180 and 270, respectively). Seroconversion is defined as post-vaccination PRNT(50) titer &gt;=10 where pre-vaccination PRNT 50 titer &lt;10, or post-vaccination PRNT(50) Titer &gt;=4-fold the pre-vaccination PRNT(50) titer value where pre-vaccination PRNT(50) titer &gt;=10. Percentage of participants with seroconversion on Days 180 and 270 are based on the number of participants in the FAS with non-missing MN assay samples at each visit. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution.</description>
          <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 180 TDV-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="90.5" lower_limit="69.6" upper_limit="98.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180 TDV-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180 TDV-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="20.0" lower_limit="0.5" upper_limit="71.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180 TDV-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="31.6" lower_limit="12.6" upper_limit="56.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="52.9" lower_limit="27.8" upper_limit="77.0"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270 TDV-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270 TDV-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270 TDV-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="57.9" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270 TDV-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="20.3" upper_limit="66.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="52.2"/>
                    <measurement group_id="O3" value="57.1" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O5" value="15.8" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O7" value="35.3" lower_limit="14.2" upper_limit="61.7"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strain Serotypes After the First and Second Vaccination</title>
        <description>Serotype-specific vaccine viremia was assessed for the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Only those serotypes and time-points where at least 1 participant had serotype-specific vaccine viremia detection were reported.</description>
        <time_frame>Baseline and at multiple time points up to Day 14 after each vaccination</time_frame>
        <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strain Serotypes After the First and Second Vaccination</title>
          <description>Serotype-specific vaccine viremia was assessed for the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Only those serotypes and time-points where at least 1 participant had serotype-specific vaccine viremia detection were reported.</description>
          <population>The FAS included all randomized participants who received at least one dose of study vaccine and for whom valid pre- and post-dosing blood samples were received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5 TDV-2 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 TDV-2 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 TDV-2 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 TDV-2 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 TDV-2 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 97 TDV-2 (n= 19, 5, 21, 3, 21, 3, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 TDV-2 (n= 19, 5, 21, 3, 21, 3, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 101 TDV-2 (n= 19, 5, 21, 3, 21, 3, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 104 TDV-2 (n= 19, 5, 21, 3, 18, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 TDV-3 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 TDV-3 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 TDV-3 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 97 TDV-3 (n= 19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 TDV-3 (n= 19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 101 TDV-3 (n= 19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 TDV-4 (n= 19, 5, 21, 3, 21, 4, 18, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 97 TDV-4 (n= 19, 5, 21, 3, 19, 4, 17, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Vaccine Viremia</title>
        <time_frame>14 Days after each vaccination</time_frame>
        <population>Due to the low prevalence of vaccine viremia, estimates of average titer duration of viral RNA within study groups would not be meaningful. Therefore as per change in planned analysis only number of participants with positive vaccine viremia of all four vaccine strain serotypes after first and second vaccination was reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Vaccine Viremia</title>
          <population>Due to the low prevalence of vaccine viremia, estimates of average titer duration of viral RNA within study groups would not be meaningful. Therefore as per change in planned analysis only number of participants with positive vaccine viremia of all four vaccine strain serotypes after first and second vaccination was reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Vaccine Viremia</title>
        <time_frame>14 Days after each vaccination</time_frame>
        <population>Due to the low prevalence of vaccine viremia, estimates of average titer levels of viral RNA within study groups would not be meaningful. Therefore as per change in planned analysis only number of participants with positive vaccine viremia of all four vaccine strain serotypes after first and second vaccination was reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O5">
            <title>High Dose Subcutaneous: TDV</title>
            <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Subcutaneous: Placebo</title>
            <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Intradermal: TDV</title>
            <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
          </group>
          <group group_id="O8">
            <title>High Dose Intradermal: Placebo</title>
            <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Titers of Vaccine Viremia</title>
          <population>Due to the low prevalence of vaccine viremia, estimates of average titer levels of viral RNA within study groups would not be meaningful. Therefore as per change in planned analysis only number of participants with positive vaccine viremia of all four vaccine strain serotypes after first and second vaccination was reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are adverse events that started after the first dose of double-blind study vaccine and up to Day 120</time_frame>
      <desc>A SAE is any untoward medical occurrence that at any dose was fatal, life-threatening, required hospitalization/prolongation of existing hospitalization, resulted in persistent/significant disability/incapacity, congenital anomaly/birth defect, medically significant or required intervention to prevent one or other of the outcomes listed here.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Subcutaneous: TDV</title>
          <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Subcutaneous: Placebo</title>
          <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Intradermal: TDV</title>
          <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8*10^3 PFU, TDV-2: 5*10^3 PFU, TDV-3: 1*10^4 PFU, and TDV-4: 2*10^5 PFU, total virus per dose: 2.2*10^5 PFU.</description>
        </group>
        <group group_id="E4">
          <title>Low Dose Intradermal: Placebo</title>
          <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="E5">
          <title>High Dose Subcutaneous: TDV</title>
          <description>TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
        </group>
        <group group_id="E6">
          <title>High Dose Subcutaneous: Placebo</title>
          <description>TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
        <group group_id="E7">
          <title>High Dose Intradermal: TDV</title>
          <description>TDV 0.1 mL, injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose). TDV is a tetravalent dengue vaccine comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2*10^4 PFU, TDV-2: 5*10^4 PFU, TDV-3: 1*10^5 PFU, and TDV-4: 3*10^5 PFU, total virus per dose: 4.7*10^5 PFU.</description>
        </group>
        <group group_id="E8">
          <title>High Dose Intradermal: Placebo</title>
          <description>TDV placebo-matching 0.1 mL injection, intradermally, once on Day 0 (first dose) and Day 90 (second dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>PHOTOPHOBIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>PYERXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE SCAB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ASYMPTOMATIC BACTERIURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>VAGINITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>BLOOD FIBRINOGEN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>PERIPHERAL COLDNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be made without Sponsorâs prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

